Brief: GT Biopharma Advances GTB-3650 Into IND-Enabling Studies
13/09/2021 12:28
Sept 13 (Reuters) - GT Biopharma Inc GTBP.O :
* GT BIOPHARMA ADVANCES GTB-3650, A SECOND-GENERATION
TRI-SPECIFIC
KILLER ENGAGER -TRIKE®, INTO IND-ENABLING STUDIES
* GT BIOPHARMA INC - ADVANCEMENT OF GTB-3650 INTO
IND-ENABLING
STUDIES, WITH WHICH IT PLANS TO SUPPLANT ONGOING PHASE 1 PROGRAM
WITH GTB-3550
Source text for Eikon: ID:nPn6KsmWPa
Further company coverage: GTBP.O
((Reuters.Briefs@thomsonreuters.com;))